drugset / Trial / NCT07456800

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

NCT07456800

Phase 1 Completed 116 enrolled PureTech
RandomizedCrossoverQuadruple-blindOther

Summary

A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.

Timeline

Start
2021-07-12
Primary completion
2022-01-01
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Deupirfenidone Unknown 550 mg
Subject Deupirfenidone Unknown 824 mg
Subject Deupirfenidone Unknown 850 mg
Comparator Pirfenidone Small molecule 801 mg

Indications

No indication recorded.